Lupin’s Karkaria On Biosimilars Pushback And Interchangeability
Questions Need For Separate Studies
Lupin's biotech president notes push-back by innovator firms against biosimilars in the US parallels that witnessed when small molecule generic competition first emerged, but remains confident that biosimilars will gain traction. The executive also sees little need for separate interchangeability studies.
You may also be interested in...
Switching German patients from one biologic to another without involving their doctor could cause patients to perceive biosimilars as having inferior safety and efficacy, a local physicians’ body is warning.
Lupin managing director Nilesh Gupta says manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.
French legislation setting out an ‘experiment’ to trial several different methods of incentivising biosimilar prescription in hospitals has been warmly welcomed by local generics and biosimilars association Gemme.